# INTerpath-014 (NCT07513376)

> A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07513376
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Non-small Cell Lung Cancer
- Interventions: Intismeran; Pembrolizumab coformulated with berahyaluronidase alfa; Placebo
- Enrollment: 876
- Primary outcome: Disease-Free Survival (DFS) as Assessed by Blinded Independent Central Review (BICR) in Participants With Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Arm A and Arm C

## Indexed commentary on INTerpath-014 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=interpath-014-nct07513376